ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

MANAGEMENT REPORT

Management's Responsibility for Financial Reporting

The accompanying financial statements have been prepared by Mackenzie Financial Corporation, as Manager of Mackenzie Ivy Foreign Equity Currency Neutral Fund (the "Fund"). The Manager is responsible for the integrity, objectivity and reliability of the data presented. This responsibility includes selecting appropriate accounting principles and making judgments and estimates consistent with IFRS Accounting Standards. The Manager is also responsible for the development of internal controls over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors (the "Board") of Mackenzie Financial Corporation is responsible for reviewing and approving the financial statements and overseeing the Manager's performance of its financial reporting responsibilities. The Board meets regularly with the Manager, internal auditors and external auditors to discuss internal controls over the financial reporting process, auditing matters and financial reporting issues.

KPMG LLP is the external auditor of the Fund. It is appointed by the Board. The external auditor has audited the financial statements in accordance with Canadian generally accepted auditing standards to enable it to express to the securityholders its opinion on the financial statements. Its report is set out below.

On behalf of Mackenzie Financial Corporation,

Manager of the Fund

Luke Gould President and Chief Executive Officer Terry Rountes Chief Financial Officer, Funds

Tug Nos

June 4, 2024

INDEPENDENT AUDITOR'S REPORT

To the Securityholders of Mackenzie Ivy Foreign Equity Currency Neutral Fund (the "Fund")

Opinion

We have audited the financial statements of the Fund, which comprise:

- the statements of financial position as at March 31, 2024 and March 31, 2023
- the statements of comprehensive income for the periods then ended as indicated in note 1
- the statements of changes in financial position for the periods then ended as indicated in note 1
- the statements of cash flows for the periods then ended as indicated in note 1 and
- notes to the financial statements, including a summary of material accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at March 31, 2024 and March 31, 2023, and its financial performance and cash flows for the periods then ended as indicated in note 1 in accordance with IFRS Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

INDEPENDENT AUDITOR'S REPORT (cont'd)

Other Information

Management is responsible for the other information. Other information comprises:

- the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the financial reporting process of the Fund.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Chartered Professional Accountants, Licensed Public Accountants Toronto, Canada

June 4, 2024

KPMG LLP

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF FINANCIAL POSITION

at March 31 (in \$ 000 except per security amounts)

	2024 \$	2023 \$
ASSETS	Þ	Ф
Current assets		
Investments at fair value	313,363	305,332
Cash and cash equivalents	29,860	41,223
Dividends receivable	271	187
Accounts receivable for investments sold	_	301
Accounts receivable for securities issued	45	20
Due from manager	_	1
Derivative assets	2,962	1,359
Taxes recoverable	184	184
Total assets	346,685	348,607
LIABILITIES		
Current liabilities		
Accounts payable for investments purchased	2	-
Accounts payable for securities redeemed	764	304
Due to manager	36	13
Derivative liabilities	4,936	2,940
Total liabilities	5,738	3,257
Net assets attributable to securityholders	340,947	345,350

STATEMENTS OF COMPREHENSIVE INCOME

for the periods ended March 31 (in \$ 000 except per security amounts)

	2024 \$	2023 \$
Income		·
Dividends	5.956	7,432
Interest income for distribution purposes	1,382	787
Other changes in fair value of investments and other net assets	,	
Net realized gain (loss)	1,934	(23,148)
Net unrealized gain (loss)	42,031	15,343
Securities lending income	12	48
Total income (loss)	51,315	462
Expenses (note 6)		
Management fees	3,959	4,468
Management fee rebates	(4)	(6)
Administration fees	508	577
Interest charges	11	1
Commissions and other portfolio transaction costs	219	294
Independent Review Committee fees	1	1
Other	9	15
Expenses before amounts absorbed by Manager	4,703	5,350
Expenses absorbed by Manager		
Net expenses	4,703	5,350
Increase (decrease) in net assets attributable to		
securityholders from operations before tax	46,612	(4,888)
Foreign withholding tax expense (recovery)	546	840
Foreign income tax expense (recovery)		
Increase (decrease) in net assets attributable to		
securityholders from operations	46,066	(5,728)

Net assets attributable to securityholders (note 3)

	Net assets at	Net assets attributable to securityholders (note 3)							
	per secu	rity	per se	ries					
	2024	2023	2024	2023					
Series A	19.46	17.17	38,198	44,294					
Series AR	13.96	12.33	2,978	2,610					
Series D	14.39	12.62	1,309	778					
Series F	20.83	18.26	127,968	132,199					
Series F5	14.05	12.92	51	129					
Series F8	11.71	11.09	1,021	1,076					
Series FB	12.83	11.23	2	1					
Series FB5	14.16	13.02	2	1					
Series J	19.36	17.04	76	132					
Series 0	23.07	20.19	50,118	42,454					
Series PW	14.20	12.48	88,263	92,102					
Series PWFB	11.91	10.44	797	762					
Series PWFB5	14.13	12.99	2	2					
Series PWR	12.20	10.73	1,421	1,126					
Series PWT5	12.17	11.23	1,229	1,061					
Series PWT8	9.27	8.82	1,211	1,262					
Series PWX	14.83	12.98	25,486	24,375					
Series PWX8	9.36	8.85	163	175					
Series T5	11.82	10.94	464	505					
Series T8	8.13	7.75	188	306					
			340,947	345,350					

Increase (decrease) in net assets attributable to securityholders from operations (note 3)

	LO SECUIT	to security notices from operations (note 3)					
	per secu	rity	per ser	ies			
	2024	2023	2024	2023			
Series A	2.19	(0.54)	5,015	(1,606)			
Series AR	1.61	(0.25)	344	(53)			
Series D	2.02	0.04	159	3			
Series F	2.66	(0.23)	17,786	(1,938)			
Series F5	1.80	1.11	8	9			
Series F8	1.58	(0.48)	147	(94)			
Series FB	1.66	(0.63)	1	(1)			
Series FB5	1.87	(0.12)	1	-			
Series J	1.73	(0.35)	10	(3)			
Series 0	3.24	0.19	7,023	388			
Series PW	1.67	(0.28)	11,242	(2,246)			
Series PWFB	1.53	(0.27)	104	(34)			
Series PWFB5	1.91	(0.09)	_	-			
Series PWR	1.47	(0.12)	154	(12)			
Series PWT5	1.50	(0.31)	141	(35)			
Series PWT8	1.08	(0.22)	150	(35)			
Series PWX	2.05	_	3,674	(2)			
Series PWX8	1.29	_	24	1			
Series T5	1.39	(0.43)	56	(24)			
Series T8	1.07	(0.63)	27	(46)			
			46,066	(5,728)			

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION

for the periods ended March 31 (in \$ 000 except per security amounts)

	Tota	al	Series	s A	Series	AR	Series	D	Series	s F
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	345,350	404,515	44,294	57,218	2,610	2,635	778	219	132,199	162,525
Increase (decrease) in net assets from operations	46,066	(5,728)	5,015	(1,606)	344	(53)	159	3	17,786	(1,938)
Distributions paid to securityholders:										
Investment income	(2,225)	-	-	-	-	-	(7)	-	(990)	-
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(282)	(505)	_	-	_	-	_	-	_	-
Management fee rebates	(4)	(6)		_		_		_	(1)	(1)
Total distributions paid to securityholders	(2,511)	(511)		_		_	(7)		(991)	(1)
Security transactions:										
Proceeds from securities issued	24,583	31,237	3,164	3,154	499	510	500	678	10,491	12,968
Reinvested distributions	2,118	116	_	-	_	-	7	-	809	1
Payments on redemption of securities	(74,659)	(84,279)	(14,275)	(14,472)	(475)	(482)	(128)	(122)	(32,326)	(41,356)
Total security transactions	(47,958)	(52,926)	(11,111)	(11,318)	24	28_	379	556_	(21,026)	(28,387)
Increase (decrease) in net assets attributable to securityholders	(4,403)	(59,165)	(6,096)	(12,924)	368	(25)	531	559	(4,231)	(30,326)
End of period	340,947	345,350	38,198	44,294	2,978	2,610	1,309	778	127,968	132,199
Increase (decrease) in fund securities (in thousands) (note 7):			Securi	ties	Securit	ties	Securit	ies	Securi	ties
Securities outstanding – beginning of period			2,580	3,262	212	209	62	17	7,241	8,846
Issued			176	191	38	43	38	55	549	743
Reinvested distributions			_	-	_	-	1	-	42	-
Redeemed			(793)	(873)	(37)	(40)	(10)	(10)	(1,688)	(2,348)
Securities outstanding – end of period			1,963	2,580	213	212	91	62	6,144	7,241

	Series	F5	Series	F8	Series	FB	Series	FB5	Series	J
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	129	28	1,076	4,130	1	36	1	1	132	147
Increase (decrease) in net assets from operations	8	9	147	(94)	1	(1)	1	-	10	(3)
Distributions paid to securityholders:										
Investment income	_	-	(8)	-	-	-	_	-	_	-
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(3)	(5)	(81)	(198)	_	-	_	-	_	-
Management fee rebates	_	_	_	_	_	_	_	_	_	_
Total distributions paid to securityholders	(3)	(5)	(89)	(198)	_	_	_	_	_	_
Security transactions:										
Proceeds from securities issued	_	117	49	89	-	-	-	-	_	-
Reinvested distributions	1	-	26	16	-	-	-	-	_	-
Payments on redemption of securities	(84)	(20)	(188)	(2,867)		(34)			(66)	(12)
Total security transactions	(83)	97	(113)	(2,762)		(34)			(66)	(12)
Increase (decrease) in net assets attributable to securityholders	(78)	101	(55)	(3,054)	1	(35)	1		(56)	(15)
End of period	51	129	1,021	1,076	2	1	2	1	76	132
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ities	Securi	ties	Securit	ies	Securi	ties	Securit	ies
Securities outstanding – beginning of period	10	2	97	338	-	3	_	-	8	8
Issued	_	9	5	8	_	-	_	-	_	-
Reinvested distributions	_	-	2	1	_	-	_	-	_	-
Redeemed	(6)	(1)	(17)	(250)		(3)			(4)	_
Securities outstanding – end of period	4	10	87	97		_		_	4	8

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

for the periods ended March 31 (in \$ 000 except per security amounts)

	Serie	s 0	Series	PW	Series P	WFB	Series PWFB5	
	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS								
Beginning of period	42,454	38,946	92,102	104,821	762	1,580	2	2
Increase (decrease) in net assets from operations	7,023	388	11,242	(2,246)	104	(34)	_	-
Distributions paid to securityholders:								
Investment income	(800)	-	_	-	(6)	-	_	-
Capital gains	_	-	_	-	_	-	_	-
Return of capital	_	-	_	-	_	-	_	-
Management fee rebates		_	(3)	(4)		(1)		
Total distributions paid to securityholders	(800)	_	(3)	(4)	(6)	(1)	_	_
Security transactions:								
Proceeds from securities issued	3,261	4,369	4,979	7,063	301	27	_	-
Reinvested distributions	783	-	3	4	5	1	_	-
Payments on redemption of securities	(2,603)	(1,249)	(20,060)	(17,536)	(369)	(811)		
Total security transactions	1,441	3,120	(15,078)	(10,469)	(63)	(783)		
Increase (decrease) in net assets attributable to securityholders	7,664	3,508	(3,839)	(12,719)	35	(818)		
End of period	50,118	42,454	88,263	92,102	797	762	2	2
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securit	ties	Secur	ities
Securities outstanding – beginning of period	2,102	1,937	7,378	8,251	73	150	_	-
Issued	157	230	378	589	29	3	-	-
Reinvested distributions	37	-	_	-	_	-	-	-
Redeemed	(123)	(65)	(1,540)	(1,462)	(35)	(80)		_
Securities outstanding – end of period	2,173	2,102	6,216	7,378	67	73		

	Series PWR		Series F	WT5	Series P	WT8	Series PWX	
	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS								
Beginning of period	1,126	1,001	1,061	1,421	1,262	1,586	24,375	26,108
Increase (decrease) in net assets from operations	154	(12)	141	(35)	150	(35)	3,674	(2)
Distributions paid to securityholders:								
Investment income	_	_	_	-	_	-	(411)	-
Capital gains	_	-	_	-	_	-	_	-
Return of capital	_	-	(52)	(72)	(96)	(125)	_	-
Management fee rebates								
Total distributions paid to securityholders			(52)	(72)	(96)	(125)	(411)	_
Security transactions:								
Proceeds from securities issued	276	189	113	28	56	33	833	1,988
Reinvested distributions	_	_	25	31	30	35	410	-
Payments on redemption of securities	(135)	(52)	(59)	(312)	(191)	(232)	(3,395)	(3,719)
Total security transactions	141	137	79	(253)	(105)	(164)	(2,152)	(1,731)
Increase (decrease) in net assets attributable to securityholders	295	125	168	(360)	(51)	(324)	1,111	(1,733)
End of period	1,421	1,126	1,229	1,061	1,211	1,262	25,486	24,375
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securit	ties	Securi	ties
Securities outstanding – beginning of period	105	92	95	118	143	161	1,878	2,020
Issued	23	18	9	2	7	4	61	161
Reinvested distributions	_	_	2	3	3	4	30	-
Redeemed	(12)	(5)	(5)	(28)	(22)	(26)	(250)	(303)
Securities outstanding – end of period	116	105	101	95	131	143	1,719	1,878

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

for the periods ended March 31 (in \$ 000 except per security amounts)

	Series I	PWX8	Series	T5	Series T8	
	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS						
Beginning of period	175	189	505	814	306	1,108
Increase (decrease) in net assets from operations	24	1	56	(24)	27	(46)
Distributions paid to securityholders:						
Investment income	(3)	-	_	-	_	-
Capital gains	_	-	_	-	_	-
Return of capital	(13)	(16)	(22)	(36)	(15)	(53)
Management fee rebates		_				_
Total distributions paid to securityholders	(16)	(16)	(22)	(36)	(15)	(53)
Security transactions:						
Proceeds from securities issued	_	-	7	13	54	11
Reinvested distributions	6	4	4	11	9	13
Payments on redemption of securities	(26)	(3)	(86)	(273)	(193)	(727)
Total security transactions	(20)	1	(75)	(249)	(130)	(703)
Increase (decrease) in net assets attributable to securityholders	(12)	(14)	(41)	(309)	(118)	(802)
End of period	163	175	464	505	188	306
Increase (decrease) in fund securities (in thousands) (note 7):	Securi		Securi		Securi	ties
Securities outstanding – beginning of period	20	20	46	69	39	128
Issued	_	-	1	1	8	-
Reinvested distributions	1	1	-	1	1	2
Redeemed	(4)	(1)	(8)	(25)	(25)	(91)
Securities outstanding – end of period	17	20	39	46	23	39

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CASH FLOWS

for the periods ended March 31 (in \$ 000)

	2024 \$	2023 \$
Cash flows from operating activities		
Net increase (decrease) in net assets attributable to		
securityholders from operations	46,066	(5,728)
Adjustments for:		
Net realized loss (gain) on investments	(1,106)	17,104
Change in net unrealized loss (gain) on investments	(41,942)	(15,295)
Purchase of investments	(100,316)	(109,966)
Proceeds from sale and maturity of investments	135,866	183,459
(Increase) decrease in accounts receivable and other assets	(83)	(36)
Increase (decrease) in accounts payable and other liabilities	23	(3)
Net cash provided by (used in) operating activities	38,508	69,535
Cash flows from financing activities		
Proceeds from securities issued	20,400	26,612
Payments on redemption of securities	(70,041)	(79,511)
Distributions paid net of reinvestments	(393)	(395)
Net cash provided by (used in) financing activities	(50,034)	(53,294)
Net increase (decrease) in cash and cash equivalents	(11,526)	16,241
Cash and cash equivalents at beginning of period	41,223	24,392
Effect of exchange rate fluctuations on cash and cash	100	500
equivalents	163	590
Cash and cash equivalents at end of period	29,860	41,223
Cook	27 000	20.001
Cash	27,808	28,021
Cash equivalents	2,052	13,202
Cash and cash equivalents at end of period	29,860	41,223
Supplementary disclosures on cash flow from operating activities:		
Dividends received	5,872	7,397
Foreign taxes paid	546	840
Interest received	1,382	787
Interest paid	11	1
•		

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS

as at March 31, 2024

EQUITIES		Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
Abbott Laboratories		Country		Charco, Chico	(4 000)	(4 000)
Accenture PLC Class A	EQUITIES					
Admiral Group PLC United Kingdom Alphabet Inc. Class A United States Communication Services S.5,568 8,705 11,358 Amphenol Corp. Class A United States Information Technology 30,885 2,851 4,828 Barry Callebant AG Switzerland Consumer Staples 1,344 3,781 2,64 Becton, Dickinson and Co. United States Berchine Hathway Inc. Class B United States Financials 12,070 8,559 11,999 Brookfield Corp. Class A (CAD) Canada Consumer Staples 192,615 10,509 10,911 Congase Faminor Congate Plannicule Corp. United States Financials 192,615 10,509 10,91 Congase Group PLC United Kingdom Consumer Discretionary 255,265 7,039 10,131 Construction Consumer Discretionary 255,265 7,039 10,131 Construction Consumer Discretionary 255,265 7,039 10,131 Construction Consumer Discretionary 255,265 7,039 10,131 Consumer Discretionary 255,265 10,131 Consumer Discretionary 255,265 10,131 Consumer Discretionary 255,265 10,131 Cons	Abbott Laboratories	United States	Health Care	42,831	6,088	6,593
Alphabet Inc. Class A United States Communication Services 55,568 8,705 11,35 Amphenno (Cn. Class A United States United States Information Inchnology 30,885 2,881 4,28 2,68 2,68 4,28 2,68 2	Accenture PLC Class A	United States	Information Technology	15,313	6,070	7,188
Amphenol Corp. Class A United States Information Technology 30,85 2,851 4,285 8,287 Calebant AG Switzerland Consumer Staples 1,344 3,781 2,66 Secton, Dickinson and Co. United States Health Care 20,216 6,335 6,77 6,335 6,77 6,75 6,75 7,73 7	Admiral Group PLC	United Kingdom	Financials			7,583
Barry Callebart MG	Alphabet Inc. Class A	United States				11,358
Becton, Dickinson and Co.		United States				4,825
Berchiner Hathaway Inc. Class B United States Financials 12,07 8,559 11,99 11,99 11,90 11,00 10,00	Barry Callebaut AG	Switzerland	Consumer Staples		3,781	2,642
Brookfield Corp. Class A (AB)		United States	Health Care			6,775
Coigate Palmolive Co. United States (Ingosom Pt C) Consumer Stapeles 103,496 10,306 12,62 Compass Group Pt C United Kingdom Consumer Stapeles 2,351 1,314 2,33 Coston Wholesale Corp. United States Consumer Staples 2,351 1,314 2,33 Danaher Corp. United States Health Care 43,4878 11,011 11,75 Balana Pt C United Kingdom Information Technology 197,177 7,134 7,98 Heineken NV Netherlands Consumer Staples 43,908 6,257 5,73 Jack Henry & Associates Inc. United States Consumer Discretionary 143,896 5,699 9,81 Jack Henry & Associates Inc. United States Financials 17,803 3,753 4,18 Jack Henry & Associates Inc. United States Financials 17,803 3,753 4,18 Jack Henry & Associates Inc. United States Financials 17,252 3,473 4,81 Jack Henry & Associates Inc. United States Consumer Staples						11,999
Compass Group PLC						10,917
Coston Wholesale Corp. United States Consumer Staples 2,351 1,314 2,335 Danaher Corp. United States Health Care 34,878 11,011 11,79 Deutsche Boerse AG Germany Financials 28,964 7,758 8,02 Heineken NV Netherlands Consumer Staples 43,908 6,257 5,73 Heineken NV Netherlands Consumer Staples 43,908 6,257 5,73 Industria de Diseno Textil SA (Inditex) Spain Consumer Staples 43,908 6,257 5,73 Jack Henry & Associates Inc. United States Financials 17,803 3,733 4,18 Johnson & Johnson United States Health Care 51,352 10,938 11,00 Merch KGAD Germany Health Care 51,352 10,938 11,00 Merch KGAD Germany Health Care 14,436 3,422 3,45 Microsoft Corp. United States Information Technology 14,646 5,454 6,836 <						12,621
Danaher Corp.			-			10,136
Deutsche Boerse AG						2,333
Halma PLC	•					11,795
Heineken NV						8,025
Industria de Diseno TextII SA (Inditex)						7,981
Jack Henry & Associates Inc. United States Financials (17,803) 3,753 4,18 (19,958) Johnson & Johnson United States Health Care 51,352 10,958 11,00 (19,58) Marsh & McLennan Companies Inc. United States Consumer Discretionary 16,220 5,413 6,19 (19,58) Merch KGAA Germany Health Care 14,436 3,422 3,45 (19,58) Microsoft Corp. United States Information Technology 14,646 5,454 8,34 (19,58) Nike Inc. Class B United States Consumer Staples 44,380 6,841 6,831 Nike Inc. Class B United States Consumer Staples 39,219 2,656 3,11 Oracle Corp. United States Information Technology 57,846 6,826 9,84 PepsiCo Inc. United States Consumer Staples 29,545 6,619 7,00 The Procter & Gamble Co. United States Lonsumer Staples 29,545 6,619 7,00 Reckitt Benckiser Group PLC United States Consumer Staples			•			
Johnson & Johnson United States Health Care 51,352 10,958 11,00 Marsh & McLennan Companies Inc. United States Financials 17,252 3,473 4,818 McDonald's Corp. United States Consumer Discretionary 16,220 5,413 6,19 Merck KGaA Germany Health Care 14,436 3,422 3,45 McGrosoft Corp. United States Information Enchnology 14,646 5,454 8,34 Nestie SA Reg. Switzerland Consumer Staples 44,380 6,841 6,38 Nike Inc. Class B United States United States United States United States Information Technology 17,846 6,825 3349 2,74 Novonesis B Denmark Materials 39,219 2,656 3,11 Oracle Corp. United States Information Technology 57,846 6,826 9,84 PepsiCo Inc. United States Consumer Staples 37,589 7,261 8,26 Reckitt Benckieser Group PLC United States Consumer Staples 37,589 7,261 8,26 Reckitt Benckieser Group PLC United Kingdom Consumer Staples 33,169 7,995 6,44 RELX PLC United Kingdom Consumer Staples 33,169 7,995 6,44 RELX PLC United Kingdom Industrials 116,690 4,451 6,83 Roche Holding AG Genusscheine Switzerland Health Care 22,591 10,381 7,79 28,00 2,646 4,363 4,96 2,640 4,363 4,96 2,440			,		5,690	
Marsh & McLennan Companies Inc.						
McDonald's Corp.						
Merck KGAA Germany Health Care 14,436 3,422 3,45						
Microsoft Corp.						
Nestifs SA Reg. Switzerland Consumer Staples 44,380 6,841 6,38 Nike Inc. Class B United States Consumer Discretionary 21,555 3,349 2,74 Novonesis B Denmark Materials 39,219 2,656 3,11 Oracle Corp. United States Information Technology 57,846 6,826 9,84 Appsion. United States Consumer Staples 29,545 6,619 7,00 The Procter & Gamble Co. United States Consumer Staples 37,589 7,261 8,26 Reckitt Benckiser Group PLC United Kingdom Consumer Staples 37,589 7,261 8,26 Reckitt Benckiser Group PLC United Kingdom Consumer Staples 33,169 7,995 6,41 Reckitt Benckiser Group PLC United Kingdom Consumer Staples 33,169 7,995 6,41 Reckitt Benckiser Group PLC United Kingdom Consumer Staples 83,169 7,995 6,41 Reckitt Benckiser Group PLC United States Information Technology 4		•				
Nike Inc. Class B United States Consumer Discretionary Naturals 31,349 3,219 3,349 3,219 2,656 3,11 3,11 3,11 3,11 3,11 3,11 3,11 3,1	•					
Novonesis B						
Oracle Corp. United States Information Technology 57,846 6,826 9,84 PepsiCo Inc. United States Consumer Staples 29,545 6,619 7,00 The Procter & Gamble Co. United States Consumer Staples 37,589 7,261 8,26 Reckift Benckiser Group PLC United Kingdom Consumer Staples 83,169 7,995 6,41 RCLX PLC United Kingdom Industrials 116,690 4,451 6,83 RCh Holding AG Genusscheine Switzerland Health Care 22,591 10,381 7,79 S&P Global Inc. United States Financials 4,540 2,439 2,61 Samsung Electronics Co. Ltd. GDR South Korea Information Technology 2,444 4,363 4,96 Seven & Holdings Co. Ltd. Japan Consumer Staples 517,650 9,529 10,21 Stryker Corp. United States Health Care 16,473 5,385 7,98 Terumo Corp. Japan Health Care 214,814 4,154 5,24<						
RepsiCo Inc. United States Consumer Staples 29,545 6,619 7,00 The Procter & Gamble Co. United Kitates Consumer Staples 37,589 7,261 8,26 Reckitt Benckiser Group PLC United Kingdom Consumer Staples 83,169 7,995 6,41 RELX PLC United Kingdom Industrials 116,690 4,451 6,83 Roche Holding AG Genusscheine Switzerland Health Care 22,591 10,381 7,79 Sev Rolobal Inc. United States Financials 4,540 2,439 2,61 Samsung Electronics Co. Ltd. GDR South Korea Information Technology 2,464 4,363 4,96 Seven & I Holdings Co. Ltd. Japan Consumer Staples 517,650 9,529 10,21 Stryker Corp. United States Health Care 16,473 5,385 7,98 Taiwan Semiconductor Manufacturing Co. Ltd. ADR Taiwan Information Technology 38,934 4,836 7,17 Terumo Corp. Japan Health Care 214,814						
The Procter & Gamble Co.	•		9,			
Reckitt Benckiser Group PLC United Kingdom United Kingdom Industrials In16,690 4,451 6,41 (6,83) RELX PLC United Kingdom Industrials In16,690 4,451 6,83 Roche Holding AG Genusscheine Switzerland Health Care 22,591 10,381 7,79 S&P Global Inc. United States Financials 4,540 2,439 2,61 Samsung Electronics Co. Ltd. GDR South Korea Information Technology 2,464 4,363 4,96 Seven & Holdings Co. Ltd. Japan Consumer Staples 517,650 9,529 10,21 Stryker Corp. United States Health Care 16,473 5,385 7,98 Taiwan Semiconductor Manufacturing Co. Ltd. ADR Taiwan Information Technology 38,934 4,836 7,17 Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 Union Pacific Corp. United States Information Technology 23,744 5,340 5,55 Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 5,773 4,028						
RELX PLC United Kingdom Roche Holding AG Genusscheine United Kingdom Switzerland Industrials Health Care Health Care 22,591 10,381 7,79 S&P Global Inc. United States Financials Financials 4,540 2,439 2,61 Samsung Electronics Co. Ltd. GDR South Korea Information Technology 2,464 4,363 4,96 Seven & i Holdings Co. Ltd. Japan Consumer Staples 517,650 9,529 10,21 Stryker Corp. United States Health Care 16,473 5,385 7,18 Taiwan Semiconductor Manufacturing Co. Ltd. ADR 1,17 Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Industrials 1 - - Veralto Corp. United States Industrials 1 - - <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
Roche Holding AG Genusscheine Switzerland Health Care 22,591 10,381 7,79 5&P Global Inc. United States Financials 4,540 2,439 2,61 4,960 2,439 2,61 4,960 2,439 2,61 4,960 2,464 4,363 4,96 4,960 2,464 4,363 4,96 4,960 2,464 4,363 4,96 4,960 2,464 4,363 4,96 4,960 2,464 4,363 4,96 2,474 4,363 4,96 4,9						
S&P Global Inc. United States Financials Information Technology 4,540 2,439 2,61 Samsung Electronics Co. Ltd. GDR South Korea Information Technology 2,464 4,363 4,96 Seven & i Holdings Co. Ltd. Japan Consumer Staples 517,650 9,529 10,21 Stryker Corp. United States Health Care 16,473 5,385 7,98 Taiwan Semiconductor Manufacturing Co. Ltd. ADR Taiwan Information Technology 38,934 4,836 7,17 Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Information Technology 23,744 5,340 5,55 Union Pacific Corp. United States Consumer Discretionary 40,446 3,543 5,55 Union Pacific Corp. United States Industrials 1 - - Visa Inc. Class A United States Industrials						
Samsung Electronics Co. Ltd. GDR South Korea Information Technology 2,464 4,363 4,96						
Seven & i Holdings Co. Ltd. Japan United States Consumer Staples 517,650 9,529 10,21 Stryker Corp. United States Health Care 16,473 5,385 7,98 Taiwan Semiconductor Manufacturing Co. Ltd. ADR Taiwan Information Technology 38,934 4,836 7,17 Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Consumer Discretionary 40,446 3,543 5,55 Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 1 - - Visa Inc. Class A United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Transaction costs (287) 265,908 313,36 D						
Stryker Corp. United States Health Care 16,473 5,385 7,98 Taiwan Semiconductor Manufacturing Co. Ltd. ADR Taiwan Information Technology 38,934 4,836 7,17 Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Consumer Discretionary 40,446 3,543 5,55 Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 1 - - Visa Inc. Class A United States Financials 23,482 7,021 8,87 W.W. Grainger Inc. United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Total equities United States Consumer Staples 42,174 2,279 3,43 </td <td>•</td> <td></td> <td></td> <td></td> <td></td> <td></td>	•					
Taiwan Semiconductor Manufacturing Co. Ltd. ADR Taiwan Japan Information Technology Health Care 38,934 4,836 7,17 Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Consumer Discretionary 40,446 3,543 5,55 Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 1 - - Visa Inc. Class A United States Financials 23,482 7,021 8,87 W.W. Grainger Inc. United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Total equities Total investments 265,621 313,36 Derivative instruments (287) 265,621 313,36 Cash and cash equivalents 29	•					
Terumo Corp. Japan Health Care 214,814 4,154 5,24 Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Consumer Discretionary 40,446 3,543 5,55 Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 1 - - Visa Inc. Class A United States Industrials 6,773 4,028 9,33 W.W. Grainger Inc. United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Total equities (287) (287) (287) (287) (287) Derivative instruments (5 ee schedule of derivative instruments) (1,97) (29,86) (1,97) Cash and cash equivalents (29,86) (29,86) (29,86) (29,86) (20,80) (20,80)						
Texas Instruments Inc. United States Information Technology 23,744 5,340 5,60 The TJX Companies Inc. United States Consumer Discretionary 40,446 3,543 5,55 Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 1 - Visa Inc. Class A United States Industrials 23,482 7,021 8,87 W.W. Grainger Inc. United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Total equities Transaction costs Transaction costs Total investments Derivative instruments (see schedule of derivative instruments) Cash and cash equivalents United States Information Technology 23,744 5,340 5,60 Tonsumer Discretionary 40,446 3,543 5,55 United States Industrials 23,070 6,412 7,68 Industrials 23,070 6,412 7,68 Industrials 1 - Consumer States Industrials 6,773 4,028 9,33 Indus						
The TJX Companies Inc. United States Unidustrials	·	•				
Union Pacific Corp. United States Industrials 23,070 6,412 7,68 Veralto Corp. United States Industrials 1 — — Visa Inc. Class A United States Financials 23,482 7,021 8,87 WW. Grainger Inc. United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Transaction costs 265,908 313,36 Transaction costs (287) — Total investments 265,621 313,36 Derivative instruments (see schedule of derivative instruments) (1,97 Cash and cash equivalents 29,86						
Veralto Corp. United States Visa Inc. Class A United States United Stat	•					
Visa Inc. Class A United States Financials 23,482 7,021 8,87 W.W. Grainger Inc. United States Industrials 6,773 4,028 9,33 Wal-Mart Stores Inc. United States Consumer Staples 42,174 2,279 3,43 Total equities 265,908 313,36 Transaction costs (287) (287) Total investments 265,621 313,36 Derivative instruments (see schedule of derivative instruments) (1,97 Cash and cash equivalents 29,86	•			•	-	7,004
W.W. Grainger Inc. United States Industrials Consumer Staples 6,773 (4,028 9,33 4,774 2,279 3,43 4,028 1,774 2,279 3,43 1,774 2,279 3,43 1,774					7 021	2 275
Wal-Mart Stores Inc. Total equities United States Consumer Staples 42,174 2,279 3,43 265,908 313,36 Transaction costs Total investments Derivative instruments (see schedule of derivative instruments) Cash and cash equivalents United States Consumer Staples 42,174 2,279 3,43 265,908 313,36						
Total equities 265,908 313,36 Transaction costs (287) Total investments 265,621 313,36 Derivative instruments (see schedule of derivative instruments) (1,97 Cash and cash equivalents 29,86				42 174		
Total investments Derivative instruments (see schedule of derivative instruments) Cash and cash equivalents 265,621 313,36 (1,97 29,86		Office Otales	Consumer Gupies			313,363
Total investments Derivative instruments (see schedule of derivative instruments) Cash and cash equivalents (1,97 Cash and cash equivalents	Transaction costs					_
(see schedule of derivative instruments) Cash and cash equivalents (1,97 29,86	Total investments			_		313,363
Cash and cash equivalents 29,86	Derivative instruments					
						(1,974)
Other accept local liabilities (20						29,860
	Other assets less liabilities				_	(302)
Net assets attributable to securityholders 340,94	Net assets attributable to securityholders				_	340,947

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SUMMARY OF INVESTMENT PORTFOLIO

MARCH 31, 2024		MARCH 31, 2023	
PORTFOLIO ALLOCATION	% OF NAV	PORTFOLIO ALLOCATION	% OF NAV
Equities	91.9	Equities	88.4
Cash and cash equivalents	8.8	Cash and short-term investments	11.9
Other assets (liabilities)	(0.7)	Other assets (liabilities)	(0.3)
REGIONAL ALLOCATION	% OF NAV	REGIONAL ALLOCATION	% OF NAV
United States	55.4	United States	50.4
United Kingdom	11.4	United Kingdom	13.2
Cash and cash equivalents	8.8	Cash and short-term investments	11.9
Switzerland	4.9	Switzerland	5.2
Japan	4.5	Japan	4.7
Germany	3.4	Germany	3.1
Canada	3.2	Australia	2.5
Spain	2.9	Canada	2.3
Taiwan	2.1	Spain	2.3
Netherlands	1.7	Hong Kong	2.3
South Korea	1.5	Taiwan	1.2
Denmark	0.9	South Korea	1.2
Other assets (liabilities)	(0.7)	Other assets (liabilities)	(0.3)
SECTOR ALLOCATION	% OF NAV	SECTOR ALLOCATION	% OF NAV
Consumer staples	19.1	Information technology	16.3
Health care	17.8	Consumer staples	15.5
Financials	17.3	Health care	15.3
Information technology	16.4	Cash and short-term investments	11.9
Consumer discretionary	10.1	Financials	11.2
Cash and cash equivalents	8.8	Industrials	11.0
Industrials	7.0	Consumer discretionary	10.9
Communication services	3.3	Communication services	5.7
Materials	0.9	Materials	2.5
Other assets (liabilities)	(0.7)	Other assets (liabilities)	(0.3)

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF DERIVATIVE INSTRUMENTS

as at March 31, 2024

Counterparty Credit Rating		cy to be d (\$ 000)	Currenc Delivered		Settlement Date	Contract Cost (\$ 000)	Current Fair Value (\$ 000)	Unrealized Gains (\$ 000)	Unrealized Losses (\$ 000)
A	1,753	CAD	(8,930)	DKK	Apr. 2, 2024	(1,753)	(1,749)	4	_
Α	987	CAD	(5,065)	DKK	Apr. 2, 2024	(987)	(992)	_	(5)
Α	13,995	DKK	(2,759)	CAD	Apr. 2, 2024	2,759	2,742	_	(17)
Α	42	CAD	(324)	SEK	Apr. 2, 2024	(42)	(41)	1	=
Α	324	SEK	(41)	CAD	Apr. 2, 2024	41	41	_	=
Α	4,100	CAD	(4,568)	AUD	Apr. 11, 2024	(4,100)	(4,033)	67	=
Α	3,307	CAD	(3,684)	AUD	Apr. 11, 2024	(3,307)	(3,253)	54	_
Α	1,375	AUD	(1,223)	CAD	Apr. 11, 2024	1,223	1,214	_	(9)
Α	4,314	AUD	(3,818)	CAD	Apr. 11, 2024	3,818	3,808	_	(10)
Α	2,438	AUD	(2,164)	CAD	Apr. 11, 2024	2,164	2,152	_	(12)
Α	1,935	CAD	(2,183)	AUD	Apr. 11, 2024	(1,935)	(1,927)	8	-
Α	2,309	AUD	(2,047)	CAD	Apr. 11, 2024	2,047	2,038	_	(9)
Α	9,706	CAD	(6,126)	CHF	Apr. 11, 2024	(9,706)	(9,211)	495	_
Α	6,565	CAD	(4,144)	CHF	Apr. 11, 2024	(6,565)	(6,231)	334	-
Α	463	CHF	(725)	CAD	Apr. 11, 2024	725	696	_	(29)
Α	2,351	CAD	(1,525)	CHF	Apr. 11, 2024	(2,351)	(2,293)	58	-
Α	2,064	CAD	(1,341)	CHF	Apr. 11, 2024	(2,064)	(2,016)	48	-
Α	1,519	CHF	(2,305)	CAD	Apr. 11, 2024	2,305	2,284	_	(21)
Α	5,484	CHF	(8,228)	CAD	Apr. 11, 2024	8,228	8,246	18	-
Α	5,669	CHF	(8,506)	CAD	Apr. 11, 2024	8,506	8,524	18	-
Α	8,900	CAD	(6,068)	EUR	Apr. 11, 2024	(8,900)	(8,869)	31	-
Α	18,204	CAD	(12,412)	EUR	Apr. 11, 2024	(18,204)	(18,141)	63	-
Α	6,068	EUR	(8,922)	CAD	Apr. 11, 2024	8,922	8,869	_	(53)
Α	12,412	EUR	(18,250)	CAD	Apr. 11, 2024	18,250	18,141	_	(109)
Α	17,212	CAD	(10,157)	GBP	Apr. 11, 2024	(17,212)	(17,363)	_	(151)
Α	23,970	CAD	(14,145)	GBP	Apr. 11, 2024	(23,970)	(24,180)	_	(210)
Α	926	GBP	(1,595)	CAD	Apr. 11, 2024	1,595	1,583	_	(12
Α	925	GBP	(1,598)	CAD	Apr. 11, 2024	1,598	1,582	_	(16)
Α	8,306	GBP	(14,254)	CAD	Apr. 11, 2024	14,254	14,198	_	(56)
Α	14,145	GBP	(24,275)	CAD	Apr. 11, 2024	24,275	24,180	_	(95
Α	2,226	CAD	(238,053)	JPY	Apr. 11, 2024	(2,226)	(2,133)	93	-
Α	14,485	CAD	(1,548,786)	JPY	Apr. 11, 2024	(14,485)	(13,878)	607	-
Α	1,872	CAD	(206,245)	JPY	Apr. 11, 2024	(1,872)	(1,848)	24	-
Α	444,298	JPY	(3,988)	CAD	Apr. 11, 2024	3,988	3,981	_	(7)
Α	1,548,786	JPY	(13,903)	CAD	Apr. 11, 2024	13,903	13,879	_	(24)
Α	10,548	CAD	(7,908)	USD	Apr. 11, 2024	(10,548)	(10,709)	_	(161
Α	102,146		(76,581)		Apr. 11, 2024	(102,146)	(103,711)	_	(1,565
Α	88,345	CAD	(66,236)	USD	Apr. 11, 2024	(88,345)	(89,698)	_	(1,353
Α	9,434	CAD	(7,073)	USD	Apr. 11, 2024	(9,434)	(9,578)	_	(144
Α	7,653		(5,687)		Apr. 11, 2024	(7,653)	(7,702)	_	(49
Α	1,985	USD	(2,675)	CAD	Apr. 11, 2024	2,675	2,688	13	_
Α	1,231	USD	(1,670)	CAD	Apr. 11, 2024	1,670	1,667	_	(3
Α	4,336	CAD	(3,211)	USD	Apr. 11, 2024	(4,336)	(4,348)	_	(12
Α	2,183	CAD	(1,623)	USD	Apr. 11, 2024	(2,183)	(2,198)	_	(15
Α	1,176	USD	(1,600)	CAD	Apr. 11, 2024	1,600	1,592	_	(8
Α	11,119	USD	(15,105)	CAD	Apr. 11, 2024	15,105	15,057	_	(48
Α	76,581		(104,041)	CAD	Apr. 11, 2024	104,041	103,708	_	(333
Α	69,938	USD	(95,035)	CAD	Apr. 11, 2024	95,035	94,712	_	(323
A	6,289	USD	(8,546)	CAD	Apr. 11, 2024	8,546	8,517	_	(29)
A	2,183	AUD	(1,938)	CAD	Jul. 16, 2024	1,938	1,930	_	(8)
A	2,050	CAD	(2,309)	AUD	Jul. 16, 2024	(2,050)	(2,042)	8	_
A	8,304		(5,484)		Jul. 16, 2024	(8,304)	(8,324)	_	(20)

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF DERIVATIVE INSTRUMENTS (cont'd)

as at March 31, 2024

Schedule of Forward Currency Contracts (cont'd)

Counterparty Credit Rating		cy to be d (\$ 000)	Currency Delivered		Settlement Date	Contract Cost (\$ 000)	Current Fair Value (\$ 000)	Unrealized Gains (\$ 000)	Unrealized Losses (\$ 000)
А	8,585	CAD	(5,669)	CHF	Jul. 16, 2024	(8,585)	(8,605)	_	(20)
Α	2,769	CAD	(13,995)	DKK	Jul. 16, 2024	(2,769)	(2,753)	16	_
Α	8,945	CAD	(6,068)	EUR	Jul. 16, 2024	(8,945)	(8,895)	50	_
Α	18,297	CAD	(12,412)	EUR	Jul. 16, 2024	(18,297)	(18,194)	103	_
Α	14,241	CAD	(8,306)	GBP	Jul. 16, 2024	(14,241)	(14,188)	53	=
Α	24,253	CAD	(14,145)	GBP	Jul. 16, 2024	(24,253)	(24,163)	90	_
Α	4,040	CAD	(444,298)	JPY	Jul. 16, 2024	(4,040)	(4,035)	5	=
Α	14,085	CAD	(1,548,786)	JPY	Jul. 16, 2024	(14,085)	(14,068)	17	_
Α	42	CAD	(324)	SEK	Jul. 16, 2024	(42)	(42)	_	=
Α	103,898	CAD	(76,581)	USD	Jul. 16, 2024	(103,898)	(103,587)	311	=
Α	15,085	CAD	(11,119)	USD	Jul. 16, 2024	(15,085)	(15,040)	45	=
Α	94,902	CAD	(69,938)	USD	Jul. 16, 2024	(94,902)	(94,601)	301	=
Α	8,534	CAD	(6,289)	USD	Jul. 16, 2024	(8,534)	(8,507)	27	_
tal forward currency	y contracts							2,962	(4,936)
tal Derivative assets									2,962
tal Derivative liabili	ties				,				(4,936)

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

1. Fiscal Periods and General Information

The information provided in these financial statements and notes thereto is for the periods ended or as at March 31, 2024 and 2023, as applicable. In the year a Fund or series is established or reinstated, 'period' represents the period from inception or reinstatement. Where a series of a Fund was terminated during either period, the information for the series is provided up to close of business on the termination date. Refer to Note 10 for the formation date of the Fund and the inception date of each series.

The Fund is organized as an open-ended mutual fund trust established under the laws of the Province of Ontario pursuant to a Declaration of Trust as amended and restated from time to time. The address of the Fund's registered office is 180 Queen Street West, Toronto, Ontario, Canada. The Fund is authorized to issue an unlimited number of units (referred to as "security" or "securities") of multiple series. Series of the Fund are available for sale under Simplified Prospectus or exempt distribution options.

Mackenzie Financial Corporation ("Mackenzie") is the manager of the Fund and is wholly owned by IGM Financial Inc., a subsidiary of Power Corporation of Canada. Canada Life Investment Management Ltd. ("CLIML") is wholly owned by The Canada Life Assurance Company ("Canada Life"), a subsidiary of Power Corporation of Canada. Investments in companies within the Power Group of companies held by the Fund are identified in the Schedule of Investments.

2. Basis of Preparation and Presentation

These audited annual financial statements ("financial statements") have been prepared in accordance with IFRS Accounting Standards ("IFRS"). A summary of the Fund's material accounting policies under IFRS is presented in Note 3.

These financial statements are presented in Canadian dollars, which is the Fund's functional and presentation currency, and rounded to the nearest thousand unless otherwise indicated. These financial statements are prepared on a going concern basis using the historical cost basis, except for financial instruments that have been measured at fair value.

These financial statements were authorized for issue by the Board of Directors of Mackenzie Financial Corporation on June 4, 2024.

3. Material Accounting Policies

The Fund adopted Disclosure of Accounting Policies Amendments to IAS 1 and IFRS Practice Statements 2 from April 1, 2023. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information disclosed in the financial statements. The amendments require the disclosure of 'material' rather than 'significant' accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies. The Manager reviewed the accounting policies and made updates to the information disclosed in certain instances in line with the amendments.

(a) Financial instruments

Financial instruments include financial assets and liabilities such as debt and equity securities, investment funds and derivatives. The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments* ("IFRS 9"). Upon initial recognition, financial instruments are classified as fair value through profit or loss ("FVTPL"). All financial instruments are recognized in the Statement of Financial Position when the Fund becomes a party to the contractual requirements of the instrument. Financial assets are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation is discharged, cancelled or expires. Investment purchase and sale transactions are recorded as of the trade date.

Financial instruments are subsequently measured at FVTPL with changes in fair value recognized in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The cost of investments is determined on a weighted average cost basis.

Realized and unrealized gains and losses on investments are calculated based on the weighted average cost of investments and exclude commissions and other portfolio transaction costs, which are separately reported in the Statement of Comprehensive Income — Commissions and other portfolio transaction costs.

Gains and losses arising from changes in the fair value of the investments are included in the Statement of Comprehensive Income for the period in which they arise.

The Fund accounts for its holdings in unlisted open-ended investment funds, private funds ("Underlying Funds") and Exchange-Traded Funds ("ETFs"), if any, at FVTPL. For private funds, the Manager will rely on the valuations provided by the managers of the private funds, which represents the Fund's proportionate share of the net assets of these private funds. The Fund's investment in Underlying Funds and ETFs, if any, is presented in the Schedule of Investments at fair value which represents the Fund's maximum exposure on these investments.

The Fund's redeemable securities contain multiple dissimilar contractual obligations and entitle securityholders to the right to redeem their interest in the Fund for cash equal to their proportionate share of the net asset value of the Fund and therefore meet the criteria for classification as financial liabilities under IAS 32 Financial Instruments: Presentation. The Fund's obligation for net assets attributable to securityholders is presented at the redemption amount.

IAS 7, Statement of Cash Flows, requires disclosures related to changes in liabilities and assets, such as the securities of the Fund, arising from financing activities. Changes in securities of the Fund, including both changes from cash flows and non-cash changes, are included in the Statement of Changes in Financial Position. Any changes in the securities not settled in cash as at the end of the period are presented as either Accounts receivable for securities issued or Accounts payable for securities redeemed in the Statement of Financial Position. These accounts receivable and accounts payable amounts typically settle shortly after period-end.

(b) Fair value measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(b) Fair value measurement (cont'd)

Investments listed on a public securities exchange or traded on an over-the-counter market are valued on the basis of the last traded market price or closing price recorded by the security exchange on which the security is principally traded, where this price falls within the quoted bid-ask spread for the investment. In circumstances where this price is not within the bid-ask spread, Mackenzie determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Mutual fund securities of an underlying fund are valued on a business day at the price calculated by the manager of such underlying fund in accordance with the constating documents of such underlying fund. Unlisted or non-exchange traded investments, or investments where a last sale or close price is unavailable or investments for which market quotations are, in Mackenzie's opinion, inaccurate, unreliable, or not reflective of all available material information, are valued at their fair value as determined by Mackenzie using appropriate and accepted industry valuation techniques including valuation models. The fair value determined using valuation models requires the use of inputs and assumptions based on observable market data including volatility and other applicable rates or prices. In limited circumstances, the fair value may be determined using valuation techniques that are not supported by observable market data.

Cash and cash equivalents which includes cash on deposit with financial institutions and short-term investments that are readily convertible to cash, are subject to an insignificant risk of changes in value, and are used by the Fund in the management of short-term commitments. Cash and cash equivalents are reported at fair value which closely approximates their amortized cost due to their nature of being highly liquid and having short terms to maturity. Bank overdraft positions are presented under current liabilities as bank indebtedness in the Statement of Financial Position.

The Fund may use derivatives (such as written options, futures, forward contracts, swaps or customized derivatives) to hedge against losses caused by changes in securities prices, interest rates or exchange rates. The Fund may also use derivatives for non-hedging purposes in order to invest indirectly in securities or financial markets, to gain exposure to other currencies, to seek to generate additional income, and/or for any other purpose considered appropriate by the Fund's portfolio manager(s), provided that the use of the derivative is consistent with the Fund's investment objectives. Any use of derivatives will comply with Canadian mutual fund laws, subject to the regulatory exemptions granted to the Fund, as applicable.

Valuations of derivative instruments are carried out daily, using normal exchange reporting sources for exchange-traded derivatives and specific broker enquiry for over-the-counter derivatives.

The value of forward contracts is the gain or loss that would be realized if, on the valuation date, the positions were to be closed out. The change in value of forward contracts is included in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The daily fluctuation of futures contracts or swaps, along with daily cash settlements made by the Fund, where applicable, are equal to the change in unrealized gains or losses that are best determined at the settlement price. These unrealized gains or losses are recorded and reported as such until the Fund closes out the contract or the contract expires. Margin paid or deposited in respect of futures contracts or swaps is reflected as a receivable in the Statement of Financial Position — Margin on derivatives. Any change in the variation margin requirement is settled daily.

Premiums paid for purchasing an option are recorded in the Statement of Financial Position – Investments at fair value.

Premiums received from writing options are included in the Statement of Financial Position as a liability and subsequently adjusted daily to fair value. If a written option expires unexercised, the premium received is recognized as a realized gain. If a written call option is exercised, the difference between the proceeds of the sale plus the value of the premium, and the cost of the security is recognized as a realized gain or loss. If a written put option is exercised, the cost of the security acquired is the exercise price of the option less the premium received.

Refer to the Schedule of Derivative Instruments and Schedule of Options Purchased/Written, as applicable, included in the Schedule of Investments for a listing of derivative and options positions as at March 31, 2024.

The Fund categorizes the fair value of its assets and liabilities into three categories, which are differentiated based on the observable nature of the inputs and extent of estimation required.

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Examples of Level 2 valuations include quoted prices for similar securities, quoted prices on inactive markets and from recognized investment dealers, and the application of factors derived from observable data to non-North American quoted prices in order to estimate the impact of differences in market closing times.

Financial instruments classified as Level 2 investments are valued based on the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Short-term investments classified as Level 2 investments are valued based on amortized cost plus accrued interest which closely approximates fair value.

The estimated fair values for these securities may be different from the values that would have been used had a ready market for the investment existed; and Level 3 – Inputs that are not based on observable market data.

The inputs are considered observable if they are developed using market data, such as publicly available information about actual events or transactions, and that reflect the assumption that market participants would use when pricing the asset or liability.

See Note 10 for the fair value classifications of the Fund.

(c) Income recognition

Interest income for distribution purposes represents the coupon interest received by the Fund which is accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds, which are amortized on a straight-line basis. Dividends are accrued as of the ex-dividend date. Unrealized gains or losses on investments, realized gains or losses on the sale of investments, including foreign exchange gains or losses on such investments, are calculated on a weighted average cost basis. Distributions received from an underlying fund are included in interest income, dividend income, realized gains (losses) on sale of investments or fee rebate income, as appropriate, on the ex-dividend or distribution date.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(c) Income recognition (cont'd)

Income, realized gains (losses) and unrealized gains (losses) are allocated daily among the series on a pro-rata basis.

(d) Commissions and other portfolio transaction costs

Commissions and other portfolio transaction costs are costs incurred to acquire, issue or dispose of financial assets or liabilities. They include fees and commissions paid to agents, exchanges, brokers, dealers and other intermediaries. The total brokerage commissions incurred by the Fund in connection with portfolio transactions for the periods, together with other transaction charges, is disclosed in the Statements of Comprehensive Income. Brokerage business is allocated to brokers based on the best net result for the Fund. Subject to this criteria, commissions may be paid to brokerage firms which provide (or pay for) certain services, other than order execution, which may include investment research, analysis and reports, and databases or software in support of these services. Where applicable and ascertainable, the value of these services generated during the periods is disclosed in Note 10. The value of certain proprietary services provided by brokers cannot be reasonably estimated.

(e) Securities lending, repurchase and reverse repurchase transactions

The Fund is permitted to enter into securities lending, repurchase and reverse repurchase transactions as set out in the Fund's Simplified Prospectus. These transactions involve the temporary exchange of securities for collateral with a commitment to redeliver the same securities on a future date.

Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on cash or securities held as collateral. Income earned from these transactions is included in the Statement of Comprehensive Income and recognized when earned. Securities lending transactions are administered by The Bank of New York Mellon (the "Securities Lending Agent"). The value of cash or securities held as collateral must be at least 102% of the fair value of the securities loaned, sold or purchased.

Note 10 summarizes the details of securities loaned and collateral received as at the end of period, as well as a reconciliation of securities lending income during the period, if applicable. Collateral received is comprised of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments, and financial institutions.

(f) Offsetting

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position only when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously. In the normal course of business, the Fund enters into various master netting agreements or similar agreements that do not meet the criteria for offsetting in the Statement of Financial Position but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or termination of the contracts. Note 10 summarizes the details of such offsetting, if applicable, subject to master netting arrangements or other similar agreements and the net impact to the Statements of Financial Position if all such rights were exercised.

Income and expenses are not offset in the Statement of Comprehensive Income unless required or permitted to by an accounting standard, as specifically disclosed in the IFRS policies of the Fund.

(g) Currency

The functional and presentation currency of the Fund is Canadian dollars. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated to Canadian dollars at the rate of exchange prevailing at the time of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statement of Comprehensive Income – Other changes in fair value of investments and other net assets – Net realized gain (loss).

The fair value of investments and other assets and liabilities, denominated in foreign currencies, are translated to Canadian dollars at the rate of exchange prevailing on each business day.

(h) Net assets attributable to securityholders per security

Net assets attributable to securityholders per security is computed by dividing the net assets attributable to securityholders of a series of securities on a business day by the total number of securities of the series outstanding on that day.

(i) Net asset value per security

The daily Net Asset Value ("NAV") of an investment fund may be calculated without reference to IFRS as per the Canadian Securities Administrators' ("CSA") regulations. The difference between NAV and Net assets attributable to securityholders (as reported in the financial statements), if any, is mainly due to differences in fair value of investments and other financial assets and liabilities and is disclosed in Note 10.

(j) Increase (decrease) in net assets attributable to securityholders from operations per security

Increase (decrease) in net assets attributable to securityholders from operations per security in the Statement of Comprehensive Income represents the increase (decrease) in net assets attributable to securityholders from operations for the period, divided by the weighted average number of securities outstanding during the period.

(k) Mergers

In a fund merger, the Fund acquires all of the assets and assumes all of the liabilities of the terminating fund at fair value in exchange for securities of the Fund on the effective date of the merger.

(I) Future accounting changes

The Fund has determined there are no material implications to the Fund's financial statements arising from IFRS issued but not yet effective.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

4. Critical Accounting Estimates and Judgments

The preparation of these financial statements requires management to make estimates and assumptions that primarily affect the valuation of investments. Estimates and assumptions are reviewed on an ongoing basis. Actual results may differ from these estimates.

The following discusses the most significant accounting judgments and estimates made in preparing the financial statements:

Use of Estimates

Fair value of securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets and are valued using valuation techniques that make use of observable data, to the extent practicable. Various valuation techniques are utilized, depending on a number of factors, including comparison with similar instruments for which observable market prices exist and recent arm's length market transactions. Key inputs and assumptions used are company specific and may include estimated discount rates and expected price volatilities. Changes in key inputs, could affect the reported fair value of these financial instruments held by the Fund.

Use of Judgments

Classification and measurement of investments

In classifying and measuring financial instruments held by the Fund, Mackenzie is required to make significant judgments in order to determine the most appropriate classification in accordance with IFRS 9. Mackenzie has assessed the Fund's business model, the manner in which all financial instruments are managed and performance evaluated as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate measurement and presentation of the Fund's financial instruments.

Functional currency

The Fund's functional and presentation currency is the Canadian dollar, which is the currency considered to best represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration the manner in which securities are issued and redeemed and how returns and performance by the Fund are measured.

Interest in unconsolidated structured entities

In determining whether an Underlying Fund or an ETF in which the Fund invests, but that it does not consolidate, meets the definition of a structured entity, Mackenzie is required to make significant judgments about whether these underlying funds have the typical characteristics of a structured entity. These Underlying Funds do meet the definition of a structured entity because:

- I. The voting rights in the Underlying Funds are not dominant factors in deciding who controls them;
- II. the activities of the Underlying Funds are restricted by their offering documents; and
- III. the Underlying Funds have narrow and well-defined investment objectives to provide investment opportunities for investors while passing on the associated risks and rewards.

As a result, such investments are accounted for at FVTPL. Note 10 summarizes the details of the Fund's interest in these Underlying Funds, if applicable.

5. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and, accordingly, is subject to tax on its income including net realized capital gains in the taxation year, which is not paid or payable to its securityholders as at the end of the taxation year. The Fund maintains a December year-end for tax purposes. The Fund may be subject to withholding taxes on foreign income. In general, the Fund treats withholding tax as a charge against income for tax purposes. The Fund will distribute sufficient amounts from net income for tax purposes, as required, so that the Fund will not pay income taxes other than refundable tax on capital gains. if applicable.

Losses of the Fund cannot be allocated to investors and are retained in the Fund for use in future years. Non-capital losses may be carried forward up to 20 years to reduce taxable income and realized capital gains of future years. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Refer to Note 10 for the Fund's loss carryforwards.

6. Management Fees and Operating Expenses

Mackenzie is paid a management fee for managing the investment portfolio, providing investment analysis and recommendations, making investment decisions, making brokerage arrangements relating to the purchase and sale of the investment portfolio and making arrangements with registered dealers for the purchase and sale of securities of the Fund by investors. The management fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Each series of the Fund, except B-Series, is charged a fixed rate annual administration fee ("Administration Fee") and in return, Mackenzie bears all of the operating expenses of the Fund, other than certain specified fund costs. The Administration Fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Other fund costs include taxes (including, but not limited to GST/HST and income tax), interest and borrowing costs, all fees and expenses of the Mackenzie Funds' Independent Review Committee (IRC), costs of complying with the regulatory requirement to produce Fund Facts, fees paid to external service providers associated with tax reclaims, refunds or the preparation of foreign tax reports on behalf of the Funds, new fees related to external services that were not commonly charged in the Canadian mutual fund industry and introduced after the date of the most recently filed simplified prospectus, and the costs of complying with any new regulatory requirements, including, without limitation, any new fees introduced after the date of the most recently filed simplified prospectus.

All expenses relating to the operation of the Fund attributable to B-Series securities will be charged to that particular series. Operating expenses include legal, audit, transfer agent, custodian, administration and trustee services, cost of financial reporting and Simplified Prospectus printing, regulatory filing fees and other miscellaneous expenses specifically attributable to the B-Series securities and any applicable taxes.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

6. Management Fees and Operating Expenses (cont'd)

Mackenzie may waive or absorb management fees and/or Administration Fees at its discretion and stop waiving or absorbing such fees at any time without notice. Refer to Note 10 for the management fee and Administration Fee rates charged to each series of securities.

7. Fund's Capital

The capital of the Fund, which is comprised of the net assets attributable to securityholders, is divided into different series with each series having an unlimited number of securities. The securities outstanding for the Fund as at March 31, 2024 and 2023 and securities issued, reinvested and redeemed for the periods are presented in the Statement of Changes in Financial Position. Mackenzie manages the capital of the Fund in accordance with the investment objectives as discussed in Note 10.

8. Financial Instruments Risk

i. Risk exposure and management

The Fund's investment activities expose it to a variety of financial risks, as defined in IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"). The Fund's exposure to financial risks is concentrated in its investments, which are presented in the Schedule of Investments, as at March 31, 2024, grouped by asset type, with geographic and sector information.

Mackenzie seeks to minimize potential adverse effects of financial risks on the Fund's performance by employing professional, experienced portfolio advisors, by monitoring the Fund's positions and market events daily, by diversifying the investment portfolio within the constraints of the Fund's investment objectives, and where applicable, by using derivatives to hedge certain risk exposures. To assist in managing risks, Mackenzie also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy, internal guidelines, and securities regulations.

ii. Liquidity risk

Liquidity risk arises when the Fund encounters difficulty in meeting its financial obligations as they become due. The Fund is exposed to liquidity risk due to potential daily cash redemptions of redeemable securities. In order to monitor the liquidity of its assets, the Fund utilizes a liquidity risk management program that calculates the number of days to convert the investments held by the Fund into cash using a multi-day liquidation approach. This liquidity risk analysis assesses the Fund's liquidity against predetermined minimum liquidity percentages established for different time periods and is monitored quarterly. In addition, the Fund has the ability to borrow up to 5% of its net assets for the purposes of funding redemptions.

In order to comply with securities regulations, the Fund must maintain at least 85% of its assets in liquid investments (i.e., investments that can be readily sold).

iii. Currency risk

Currency risk is the risk that financial instruments which are denominated or exchanged in a currency other than the Canadian dollar, which is the Fund's functional currency, will fluctuate due to changes in exchange rates. Generally, foreign denominated investments increase in value when the value of the Canadian dollar (relative to foreign currencies) falls. Conversely, when the value of the Canadian dollar rises relative to foreign currencies, the values of foreign denominated investments fall.

Note 10 indicates the foreign currencies, if applicable, to which the Fund had significant exposure, including both monetary and non-monetary financial instruments, and illustrates the potential impact, in Canadian dollar terms, to the Fund's net assets had the Canadian dollar strengthened or weakened by 5% relative to all foreign currencies, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to currency risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts including forward currency contracts. Other financial assets and liabilities (including dividends and interest receivable, and receivables/payables for investments sold/purchased) that are denominated in foreign currencies do not expose the Fund to significant currency risk.

iv. Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The Fund is exposed to the risk that the value of interest-bearing financial instruments will fluctuate due to changes in the prevailing levels of market interest rates. Generally, these securities increase in value when interest rates fall and decrease in value when interest rates rise.

If significant, Note 10 summarizes the Fund's interest-bearing financial instruments by remaining term to maturity and illustrates the potential impact to the Fund's net assets had prevailing interest rates increased or decreased by 1%, assuming a parallel shift in the yield curve, all other variables held constant. The Fund's sensitivity to interest rate changes was estimated using weighted average duration. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to interest rate risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts. Cash and cash equivalents and other money market instruments are short term in nature and are not generally subject to significant amounts of interest rate risk.

v. Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment. All investments present a risk of loss of capital. This risk is managed through a careful selection of investments and other financial instruments within the parameters of the investment strategies. Except for certain derivative contracts, the maximum risk resulting from financial instruments is equivalent to their fair value. The maximum risk of loss on certain derivative contracts such as forwards, swaps, and futures contracts is equal to their notional values. In the case of written call (put) options and short futures contracts, the loss to the Fund continues to increase, theoretically without limit, as the fair value of the underlying interest increases (decreases). However, these instruments are generally used within the overall investment management process to manage the risk from the underlying investments and do not typically increase the overall risk of loss to the Fund. This risk is mitigated by ensuring that the Fund holds a combination of the underlying interest, cash cover and/or margin that is equal to or greater than the value of the derivative contract.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

8. Financial Instruments Risk (cont'd)

v. Other price risk (cont'd)

Other price risk typically arises from exposure to equity and commodity securities. If significant, Note 10 illustrates the potential increase or decrease in the Fund's net assets, had the prices on the respective exchanges for these securities increased or decreased by 10%, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to other price risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts.

vi. Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund. Note 10 summarizes the Fund's exposure, if applicable and significant, to credit risk.

If presented, credit ratings and rating categories are based on ratings issued by a designated rating organization. Indirect exposure to credit risk may arise from fixed-income securities, such as bonds, held by underlying funds and ETFs, if any. The fair value of debt securities includes consideration of the creditworthiness of the debt issuer.

To minimize the possibility of settlement default, securities are exchanged for payment simultaneously, where market practices permit, through the facilities of a central depository and/or clearing agency where customary.

The carrying amount of investments and other assets represents the maximum credit risk exposure as at the date of the Statement of Financial Position. The Fund may enter into securities lending transactions with counterparties and it may also be exposed to credit risk from the counterparties to the derivative instruments it may use. Credit risk associated with these transactions is considered minimal as all counterparties have a rating equivalent to a designated rating organization's credit rating of not less than A-1 (low) on their short-term debt and of A on their long-term debt, as applicable.

vii. Underlying funds

The Fund may invest in underlying funds and may be indirectly exposed to currency risk, interest rate risk, other price risk and credit risk from fluctuations in the value of financial instruments held by the underlying funds. Note 10 summarizes the Fund's exposure, if applicable and significant, to these risks from underlying funds.

9. Other Information

Abbreviations

Foreign currencies, if any, are presented in these financial statements using the following abbreviated currency codes:

Currency Code	Description	Currency Code	Description	Currency Code	Description
AUD	Australian dollars	HUF	Hungarian forint	PLN	Polish zloty
AED	United Arab Emirates Dirham	IDR	Indonesian rupiah	QAR	Qatar Rial
BRL	Brazilian real	ILS	Israeli shekel	RON	Romanian leu
CAD	Canadian dollars	INR	Indian rupee	RUB	Russian ruble
CHF	Swiss franc	JPY	Japanese yen	SAR	Saudi riyal
CZK	Czech koruna	KOR	South Korean won	SEK	Swedish krona
CLP	Chilean peso	MXN	Mexican peso	SGD	Singapore dollars
CNY	Chinese yuan	MYR	Malaysian ringgit	ТНВ	Thailand baht
СОР	Colombian peso	NGN	Nigerian naira	TRL	Turkish lira
DKK	Danish krone	NOK	Norwegian krona	USD	United States dollars
EGP	Egyptian pound	NTD	New Taiwan dollar	VND	Vietnamese dong
EUR	Euro	NZD	New Zealand dollars	ZAR	South African rand
GBP	United Kingdom pounds	PEN	Peruvian nuevo sol	ZMW	Zambian kwacha
GHS	Ghana Cedi	PHP	Philippine peso		·
HKD	Hong Kong dollars	PKR	Pakistani rupee		

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a))
- (a) Fund Formation and Series Information

Date of Formation of the Predecessor Fund: October 26, 2000

Date of Formation of the Predecessor Fund is the start date of the applicable series of the Predecessor Fund, Mackenzie Ivy Foreign Equity Currency Neutral Class, which was merged into the corresponding series of the Fund on July 30, 2021.

The Fund may issue an unlimited number of securities of each series. The number of issued and outstanding securities of each series is disclosed in the Statements of Changes in Financial Position.

Series Offered by Mackenzie Financial Corporation (180 Queen Street West, Toronto, Ontario, M5V 3K1; 1-800-387-0614; www.mackenzieinvestments.com)

Series A, Series T5 and Series T8 securities are offered to retail investors investing a minimum of \$500 (\$5,000 for Series T5 and Series T8). Investors in Series T5 and Series T8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series AR securities are offered to retail investors in a Registered Disability Savings Plan offered by Mackenzie.

Series D securities are offered to retail investors investing a minimum of \$500 through a discount brokerage or other account approved by Mackenzie.

Series F, Series F5 and Series F8 securities are offered to investors who are enrolled in a dealer-sponsored fee-for-service or wrap program, who are subject to an asset-based fee rather than commissions on each transaction and who invest at least \$500 (\$5,000 for Series F5 and Series F8); they are also available to employees of Mackenzie and its subsidiaries, and directors of Mackenzie. Investors in Series F5 and Series F8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series FB and Series FB5 securities are offered to retail investors investing a minimum of \$500. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series FB5 securities also want to receive a monthly cash flow of 5% per year.

Series O securities are offered only to investors investing a minimum of \$500,000 who are enrolled in Mackenzie Portfolio Architecture Service or Open Architecture Service; certain institutional investors; investors in a qualified group plan, and certain qualifying employees of Mackenzie and its subsidiaries.

Series PW, Series PWT5 and Series PWT8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors in Series PWT5 and Series PWT8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series PWFB and Series PWFB5 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWFB5 securities also want to receive a monthly cash flow of 5% per year.

Series PWR securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000 in a Registered Disability Savings Plan offered by Mackenzie.

Series PWX and Series PWX8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWX8 securities also want to receive a monthly cash flow of 8% per year.

Series J securities are no longer available for sale.

Effective June 1, 2022, an investor may purchase the Fund only under a sales charge purchase option. The sales charge under the sales charge purchase option is negotiated by the investor with their dealer. Securities purchased before June 1, 2022, under the redemption charge purchase option, low-load 3 purchase option and low-load 2 purchase option (collectively the "deferred sales charge purchase options") may continue to be held in investor accounts. Investors may switch from securities of a Mackenzie fund previously purchased under these deferred sales charge purchase options to securities of other Mackenzie funds, under the same purchase option, until such time as the redemption schedule has expired. For further details, please refer to the Fund's Simplified Prospectus and Fund Facts.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (a) Fund Formation and Series Information (cont'd)

		ı
Inca	ption	
IIICC	D LIVII	,

Series	Reinstatement Date (1)	Management Fee	Administration Fee
Series A	August 27, 2007	2.00%	0.28%
Series AR	October 18, 2013	2.00%	0.31%
Series D	March 19, 2014	1.00% (4)	0.20%
Series F	September 19, 2007	0.80%	0.15%
Series F5	June 1, 2018	0.80%	0.15%
Series F8	June 1, 2018	0.80%	0.15%
Series FB	October 26, 2015	1.00%	0.28%
Series FB5	January 15, 2019	1.00%	0.28%
Series J	November 25, 2010	1.75%	0.25%
Series 0	October 12, 2007	_ (2)	n/a
Series PW	October 17, 2013	1.80%	0.15%
Series PWFB	April 3, 2017	0.80%	0.15%
Series PWFB5	January 15, 2019	0.80%	0.15%
Series PWR	April 1, 2019	1.80%	0.15%
Series PWT5	April 3, 2017	1.80%	0.15%
Series PWT8	April 15, 2014	1.80%	0.15%
Series PWX	December 13, 2013	_ (3)	_ (3)
Series PWX8	December 20, 2013	_ (3)	_ (3)
Series T5	April 30, 2008	2.00%	0.28%
Series T8	January 28, 2008	2.00%	0.28%

⁽¹⁾ This is the inception date of the applicable series of Mackenzie lvy Foreign Equity Currency Neutral Class.

Expiration Date of Non-Capital Losses

Total	Total															
Capital	Non-Capital	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	
Loss \$	Loss \$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	
4,511	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_

⁽²⁾ This fee is negotiable and payable directly to Mackenzie by investors in this series.

⁽³⁾ This fee is payable directly to Mackenzie by investors in this series through redemptions of their securities.

⁽⁴⁾ Prior to April 4, 2022, the management fee for Series D was charged to the Fund at a rate of 1.25%.

⁽b) Tax Loss Carryforwards

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a)) (cont'd)

(c) Securities Lending

	March 31, 2024	March 31, 2023
	(\$)	(\$)
Value of securities loaned	10,094	191
Value of collateral received	10,570	203

	March 31, 2024		March 31, 2023	
	(\$)	(%)	(\$)	(%)
Gross securities lending income	14	100.0	59	100.0
Tax withheld	_	_	(1)	(1.7)
	14	100.0	58	98.3
Payments to securities lending agent	(2)	(14.3)	(10)	(16.9)
Securities lending income	12	85.7	48	81.4

(d) Commissions

	(\$)
March 31, 2024	55
March 31, 2023	93

(e) Risks Associated with Financial Instruments

i. Risk exposure and management

The Fund seeks long-term capital growth, while trying to protect capital, by investing in equities of companies located anywhere in the world.

The Fund's investments generally do not include investments in emerging markets, and securities of U.S. companies will usually form the largest percentage of assets from any geographic area. The Fund seeks to eliminate substantially all its foreign currency exposure.

ii. Currency risk

The tables below summarize the Fund's exposure to currency risk.

			Marc	h 31, 2024				
-						Impact on	net assets	
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthene	ed by 5% %	Weakene (\$)	d by 5%
EUR	27,017	2,009	(27,089)	1,937				
GBP	38,945	161	(38,351)	755				
USD	201,092	21,294	(221,738)	648				
JPY	15,461	3,254	(18,102)	613				
DKK	3,113	_	(2,752)	361				
HKD	_	275	_	275				
CHF	16,818	181	(16,930)	69				
AUD	_	113	(113)	_				
SEK	_	41	(42)	(1)				
Total	302,446	27,328	(325,117)	4,657				
% of Net Assets	88.7	8.0	(95.4)	1.3				
Total currency rate sensitivit	у				(233)	(0.1)	233	0.1

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (e) Risks Associated with Financial Instruments (cont'd)

ii. Currency risk (cont'd)

March 31, 2023

				_	Impact on net assets			
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthened by 5% Weakened (\$) % (\$)		ed by 5%	
HKD	7,862	_	(7,642)	220				
GBP	45,732	_	(45,529)	203				
AUD	8,504	_	(8,402)	102				
DKK	_	_	1	1				
CHF	17,874	_	(17,973)	(99)				
JPY	16,243	4,638	(20,711)	170				
EUR	18,740	4,436	(23,281)	(105)				
USD	182,343	29,155	(209,181)	2,317				
Total	297,298	38,229	(332,718)	2,809				
% of Net Assets	86.1	11.1	(96.3)	0.9				
Total currency rate sen	sitivity				(140)	_	140	

^{*} Includes both monetary and non-monetary financial instruments

iii. Interest rate risk

As at March 31, 2024 and 2023, the Fund did not have a significant exposure to interest rate risk.

iv. Other price risk

The table below summarizes the Fund's exposure to other price risk.

	Increased by	10%	Decreased by 10%		
Impact on net assets	(\$)	(%)	(\$)	(%)	
March 31, 2024	31,336	9.2	(31,336)	(9.2)	
March 31, 2023	30,533	8.8	(30,533)	(8.8)	

v. Credit risk

As at March 31, 2024 and 2023, the Fund did not have a significant exposure to credit risk.

(f) Fair Value Classification

The table below summarizes the fair value of the Fund's financial instruments using the fair value hierarchy described in note 3.

	March 31, 2024				March 31, 2023			
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	313,363	_	_	313,363	186,360	118,972	_	305,332
Derivative assets	_	2,962	_	2,962	_	1,359	_	1,359
Derivative liabilities	_	(4,936)	_	(4,936)	_	(2,940)	_	(2,940)
Short-term investments	_	2,052	_	2,052	_	13,202	_	13,202
Total	313,363	78	_	313,441	186,360	130,593	_	316,953

The Fund's policy is to recognize transfers into and transfers out of fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer.

During the period ended March 31, 2024, non-North American equities frequently transferred between Level 1 (unadjusted quoted market prices) and Level 2 (adjusted market prices). As at March 31, 2024, these securities were classified as Level 1 (2023 – Level 2).

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (g) Investments by the Manager and Affiliates

The investments held by the Manager, other funds managed by the Manager, and funds managed by affiliates of the Manager, investing in series CL, IG or S of the Fund, as applicable (as described in *Fund Formation and Series Information* in note 10), were as follows:

	March 31, 2024	March 31, 2023 (\$)	
	(\$)		
The Manager	10	11	
Other funds managed by the Manager	_	_	
Funds managed by affiliates of the Manager	_	_	

(h) Offsetting of Financial Assets and Liabilities

The tables below present financial assets and financial liabilities that are subject to master netting arrangements or other similar agreements and the net impact on the Fund's Statements of Financial Position if all set-off rights were exercised as part of future events such as bankruptcy or termination of contracts. No amounts were offset in the financial statements.

	March 31, 2024				
	Gross amount of assets/liabilities (\$)	Amount available for offset (\$)	Margin (\$)	Net amount (\$)	
Unrealized gains on derivative contracts	356	(221)	-	135	
Unrealized losses on derivative contracts	(2,119)	221	-	(1,898)	
Liability for options written	-	_	_	_	
Total	(1,763)	-	-	(1,763)	

		March 31, 2023				
	Gross amount of assets/liabilities (\$)	Amount available for offset (\$)	Margin (\$)	Net amount (\$)		
Unrealized gains on derivative contracts	42	(42)	-	-		
Unrealized losses on derivative contracts	(610)	42	-	(568)		
Liability for options written	-	_	_	_		
Total	(568)	-	-	(568)		

(i) Interest in Unconsolidated Structured Entities

As at March 31, 2024 and 2023, the Fund had no investments in Underlying Funds.